Document Detail

Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training.
MedLine Citation:
PMID:  16750472     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Duloxetine is a serotonin and norepinephrine reuptake inhibitor and may be useful for treating women with stress urinary incontinence (SUI) in general practice. OBJECTIVE: The objective of this study was to examine the cost-effectiveness of 2 duloxetine strategies (duloxetine alone and duloxetine after inadequate response to pelvic floor muscle training [PFMT]) compared with PFMT or no treatment for women aged>or=50 years with SUI. METHODS: A Markov model with a 3-month cycle length was developed, with a time horizon of 5 years. Incontinence severity was based on incontinence episode frequency per week (IEF/week). Four SUI health states were distinguished in the model: no SUI (0 incontinence episode [IE] per week), mild SUI (19 IEs/week), moderate SUI (10-25 IEs/week), and severe SUI (>or=26 IEs/week). Transition probabilities were calculated, based on published evidence, expert opinion, and demographic data. Outcomes were expected total societal costs and expected IEs. The analysis was performed from the societal perspective of The Netherlands, and all costs were reported in year-2002 euros. One-way sensitivity and probabilistic sensitivity analyses were performed. RESULTS: In the model, providing PFMT cost euro0.03/IE avoided, compared with no treatment. Duloxetine after inadequate PFMT cost euro3.81/IE avoided, compared with PFMT One-way sensitivity analyses indicated that these results were robust regarding variation in age, IEF/week, and discount rate. Below the ceiling ratio of euro3.65/IE avoided, PFMT had the highest probability of being cost-effective. With higher ceiling ratios, duloxetine after inadequate PFMT had the highest cost-effectiveness probability. CONCLUSIONS: Treating patients with duloxetine after inadequate PFMT response yielded additional health effects in the model, but would require society in The Netherlands to pay euro3.81/IE avoided for women aged>or=50 years with SUI being treated in general practice. It is up to policy-makers to determine whether this ratio would be acceptable.
Daniëlle E M Brunenberg; Manuela A Joore; Christiaan P W M Veraart; Bary C M Berghmans; C Huub van der Vaart; Johan L Severens
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical therapeutics     Volume:  28     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-06-05     Completed Date:  2006-06-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  604-18     Citation Subset:  IM    
Department of Clinical Epidemiology and Medical Technology Assessment, University Hospital Maastricht, Maastricht, The Netherlands, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic Uptake Inhibitors / adverse effects,  economics*,  therapeutic use*
Cost-Benefit Analysis
Double-Blind Method
Exercise Therapy / economics*
Markov Chains
Middle Aged
Models, Statistical
Patient Dropouts
Pelvic Floor / physiology*
Prospective Studies
Thiophenes / adverse effects,  economics*,  therapeutic use*
Treatment Outcome
Urinary Incontinence / drug therapy,  economics*,  therapy*
Reg. No./Substance:
0/Adrenergic Uptake Inhibitors; 0/Thiophenes; 116539-58-3/duloxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Retrospective review of sex differences in the management of dyslipidemia in coronary heart disease:...
Next Document:  Drugs and falls in community-dwelling older people: a national veterans study.